GL1X · GenesisL1 explorer

MolNFT v1 · #80569 · protein

Fab-antibody complex

3U0T · Ponezumab lc Fab: “Fab-antibody complex”. X-ray diffraction, 13 pockets (best druggability 0.80). MolNFT v1 #80569 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
3U0T
Type
protein
Length
875 residues
Chains
6
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ponezumab lc Fab; Ponezumab hc Fab; Amyloid beta A4 protein
UniProt
P05067
Pockets
13 · best druggability 0.80

Structure

x-ray diffraction · 5 distinct chains · 6% helix, 51% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
CPonezumab lc Fabprotein2195% helix, 51% strand—
DPonezumab hc Fabprotein2076% helix, 54% strand—
E, FAmyloid beta A4 proteinprotein110% helix, 0% strandP05067
APonezumab lc Fabprotein2186% helix, 51% strand—
BPonezumab hc Fabprotein2097% helix, 52% strand—

Pockets

13 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14920.800.8760empty
26140.780.8470empty
32210.510.7634empty
4520.510.8821empty
5750.400.7817empty

Interfaces

11 interfaces between chains.

  • C–D · 1780 Ų buried · 12 hydrogen bonds · protein-protein
  • A–B · 1762 Ų buried · 12 hydrogen bonds · protein-protein
  • D–E · 456 Ų buried · 9 hydrogen bonds · protein-protein
  • B–F · 420 Ų buried · 9 hydrogen bonds · protein-protein
  • D–A · 371 Ų buried · 3 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 10 disulfide (disulfide).

Compared structures

  • 3U0T · Fab-antibody complex · the same entry in another collection · chain F against F, TM-score 1.00
  • P05067 · AlphaFold monomer V2.0 prediction for amyloid-beta precursor protein (P05067) · a predicted model of the same protein · chain F against A, TM-score 0.34

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.